Wilson’s Disease

Prime Medicine’s Q3 2025 report highlights advancements in its gene editing programs. IND/CTA filing for Wilson’s Disease is expected in H1 2026, with initial data in 2027. PM647 was nominated for AATD, targeting IND/CTA in mid-2026. Preclinical PM577 data will be presented at AASLD. The company reported a $50.6M net loss but holds $227.0M in cash, projected to fund operations into 2027. Matthew Hawryluk was appointed Chief Business Officer. A KOL event on WD strategy is scheduled for November 12, 2025.